|
1
|
World Health Organization (WHO): WHO
COVID-19 Dashboard. WHO, Geneva. https://covid19.who.int. Accessed December 23,
2021.
|
|
2
|
Benderra MA, Aparicio A, Leblanc J,
Wassermann D, Kempf E, Galula G, Bernaux M, Canellas A, Moreau T,
Bellamine A, et al: Clinical characteristics, care trajectories and
mortality rate of SARS-CoV-2 infected cancer patients: A
multicenter cohort study. Cancers (Basel). 13(4749)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Armstrong RA, Kane AD and Cook TM:
Outcomes from intensive care in patients with COVID-19: A
systematic review and meta-analysis of observational studies.
Anaesthesia. 75:1340–1349. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gupta S, Hayek SS, Wang W, Chan L, Mathews
KS, Melamed ML, Brenner SK, Leonberg-Yoo A, Schenck EJ, Radbel J,
et al: Factors associated with death in critically ill patients
with coronavirus disease 2019 in the US. JAMA Intern Med.
180:1436–1447. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Russell B, Moss CL, Palmer K, Sylva R,
D'Souza A, Wylie H, Haire A, Cahill F, Steel R, Hoyes A, et al:
COVID-19 risk factors for cancer patients: A first report with
comparator data from COVID-19 negative cancer patients. Cancers
(Basel). 13(2479)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lei H, Yang Y, Zhou W, Zhang M, Shen Y,
Tao D, Wang L, Lei Q, Wang Y and Wu Y: Higher mortality in lung
cancer patients with COVID-19? A systematic review and
meta-analysis. Lung Cancer. 157:60–65. 2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kuderer NM, Choueiri TK, Shah DP, Shyr Y,
Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G
Jr, et al: Clinical impact of COVID-19 on patients with cancer
(CCC19): A cohort study. Lancet. 395:1907–1918. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z,
Zhang Z, You H, Wu M, Zheng Q, et al: Patients with cancer appear
more vulnerable to SARS-CoV-2: A multicenter study during the
COVID-19 outbreak. Cancer Discov. 10:783–791. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zhang L, Zhu F, Xie L, Wang C, Wang J,
Chen R, Jia P, Guan HQ, Peng L, Chen Y, et al: Clinical
characteristics of COVID-19-infected cancer patients: A
retrospective case study in three hospitals within Wuhan, China.
Ann Oncol. 31:894–901. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Robinson A, Gyawali B and Booth CM: Risk
of COVID-19 in patients with cancer. JAMA Oncol. 6:1471–1472.
2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Tian J, Yuan X, Xiao J, Zhong Q, Yang C,
Liu B, Cai Y, Lu Z, Wang J, Wang Y, et al: Clinical characteristics
and risk factors associated with COVID-19 disease severity in
patients with cancer in Wuhan, China: A multicentre, retrospective,
cohort study. Lancet Oncol. 21:893–903. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Grivas P, Khaki AR, Wise-Draper TM, French
B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, et
al: Association of clinical factors and recent anticancer therapy
with COVID-19 severity among patients with cancer: A report from
the COVID-19 and cancer consortium. Ann Oncol. 32:787–800.
2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lee LY, Cazier JB, Angelis V, Arnold R,
Bisht V, Campton NA, Chackathayil J, Cheng VW, Curley HM, Fittall
MW, et al: COVID-19 mortality in patients with cancer on
chemotherapy or other anticancer treatments: A prospective cohort
study. Lancet. 395:1919–1926. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wang B and Huang Y: Immunotherapy or other
anti-cancer treatments and risk of exacerbation and mortality in
cancer patients with COVID-19: A systematic review and
meta-analysis. Oncoimmunology. 9(1824646)2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Long QX, Tang XJ, Shi QL, Li Q, Deng HJ,
Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, et al: Clinical and
immunological assessment of asymptomatic SARS-CoV-2 infections. Nat
Med. 26:1200–1204. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
McMahon A and Robb NC: Reinfection with
SARS-CoV-2: Discrete SIR (susceptible, infected, recovered)
modeling using empirical infection data. JMIR Public Health
Surveill. 6(e21168)2020.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Kromm S and Bourassa L: Can people with
previous COVID-19 infection become re-infected by the SARS-CoV-2
virus? (updated May 12, 2020), Alberta Health Services, COVID-19
Scentific Advisory Group, https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-reinfection-rapid-review.pdf.
Accessed December 21, 2021.
|
|
18
|
Russell B, Moss CL, Shah V, Ko TK, Palmer
K, Sylva R, George G, Monroy-Iglesias MJ, Patten P, Ceesay MM, et
al: Risk of COVID-19 death in cancer patients: An analysis from
Guy's cancer centre and King's college hospital in London. Br J
Cancer 125, 939-947, 2021.
|
|
19
|
Aydillo T, Gonzalez-Reiche AS, Aslam S,
van de Guchte A, Khan Z, Obla A, Dutta J, van Bakel H, Aberg J,
García-Sastre A, et al: Shedding of viable SARS-CoV-2 after
immunosuppressive therapy for cancer. N Engl J Med. 383:2586–2588.
2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Rogado J, Gullón P, Obispo B, Serrano G
and Lara MÁ: Prolonged SARS-CoV-2 viral shedding in patients with
solid tumours and associated factors. Eur J Cancer. 148:58–60.
2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Smith SM, Wachter K, Burris HA III,
Schilsky RL, George DJ, Peterson DE, Johnson ML, Markham MJ,
Mileham KF, Beg MS, et al: Clinical cancer advances 2021: ASCO's
report on progress against cancer. J Clin Oncol. 39:1165–1184.
2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
McIntosh K: COVID-19 epidemiology,
virology and prevention. In: UpToDate, Martin S. Hirsch (ed).
UpTodate, Waltham, MA. https://www.uptodate.com/contents/covid-19-epidemiology-virology-and-prevention.
Accessed December 21, 2021.
|
|
23
|
Barrière J, Gal J, Hoch B, Cassuto O,
Leysalle A, Chamorey E and Borchiellini D: Acceptance of SARS-CoV-2
vaccination among French patients with cancer: A cross-sectional
survey. Ann Oncol. 32:673–674. 2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Brodziak A, Sigorski D, Osmola M, Wilk M,
Gawlik-Urban A, Kiszka J, Machulska-Ciuraj K and Sobczuk P:
Attitudes of patients with cancer towards vaccinations-results of
online survey with special focus on the vaccination against
COVID-19. Vaccines (Basel). 9(411)2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Gheorghe AS, Negru ŞM, Nițipir C, Mazilu
L, Marinca M, Gafton B, Ciuleanu TE, Schenker M, Dragomir RD,
Gheorghe AD, et al: Knowledge, attitudes and practices related to
the COVID-19 outbreak among Romanian adults with cancer: a
cross-sectional national survey. ESMO Open.
6(100027)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chun JY, Kim SI, Park EY, Park SY, Koh SJ,
Cha Y, Yoo HJ, Joung JY, Yoon HM, Eom BW, et al: Cancer patients'
willingness to take COVID-19 vaccination: A nationwide multicenter
survey in Korea. Cancers (Basel). 13(3883)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Pleyer C, Ali MA, Cohen JI, Tian X, Soto
S, Ahn IE, Gaglione EM, Nierman P, Marti GE, Hesdorffer C, et al:
Effect of Bruton tyrosine kinase inhibitor on efficacy of
adjuvanted recombinant hepatitis B and zoster vaccines. Blood.
137:185–189. 2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wu JT, La J, Branch-Elliman W, Huhmann LB,
Han SS, Parmigiani G, Tuck DP, Brophy MT, Do NV, Lin AY, et al:
Association of COVID-19 vaccination with SARS-CoV-2 infection in
patients with cancer: A US nationwide veterans affairs study. JAMA
Oncol. 8:281–286. 2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Waldhorn I, Ben-Aharon I, Holland R, Peer
A, Halberthal M and Goshen-Lago TG: 15590 - Efficacy and toxicity
of BNT162b2 vaccine in cancer patients. Ann Oncol. 32:S1129–S1163.
2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Oosting S, Van der Veldt AAM,
GeurtsvanKessel CH, Fehrmann RSN, van Binnendijk RS, Dingemans AMC,
Smit EFF, Hiltermann TJN, den Hartog G, Jalving M, et al: LBA8
vaccination against SARS-CoV-2 in patients receiving chemotherapy,
immunotherapy, or chemo-immunotherapy for solid tumors. Ann Oncol.
32(S1337)2021.
|
|
31
|
Monin L, Laing AG, Muñoz-Ruiz M, McKenzie
DR, Del Molino Del Barrio I, Alaguthurai T, Domingo-Vila C, Hayday
TS, Graham C, Seow J, et al: Safety and immunogenicity of one
versus two doses of the COVID-19 vaccine BNT162b2 for patients with
cancer: Interim analysis of a prospective observational study.
Lancet Oncol. 22:765–778. 2021.PubMed/NCBI View Article : Google Scholar
|
